abs240.txt	importance		preferential	delivery	of	docetaxel	to	tumors	by	prostate-specificmembrane	antigen	(psma)-targeted	nanoparticles	is	clinically	effective	and	theselective	reduction	psma-positive	circulating	tumor	cells	(ctcs)	aftertreatment	has	implications	for	patient	selection	disease	monitoring	objective	determine	the	safety	efficacy	bind-014	a	psma-directeddocetaxel-containing	nanoparticle	in	patients	with	metastaticcastration-resistant	prostate	cancer	(mcrpc)	design	setting	participants	multicenter	open-label	phase	2	clinicaltrial	42	chemotherapy-naive	progressing	mcrpc	after	treatmentwith	abiraterone	acetate	and/or	enzalutamide	was	conducted	from	june	24	2013	tojune	10	2016	intervention	treatment	at	dosage	60	mg/m2	givenintravenously	on	day	1	21-day	cycles	combination	prednisone	untildisease	progression	or	unacceptable	toxic	effects	occurred	main	outcomes	measures	primary	end	point	radiographicprogression-free	survival	according	working	group	2recommendations	response	evaluation	criteria	solid	version	secondary	points	included	prostate-specific	(psa)	(≥50%reduction	baseline)	changes	ctc	number	(from	≥5	<5	per	7	5ml	blood)	(cellsearch)	based	psma	expression	levelson	ctcs	were	also	evaluated	(epic	sciences)	results	among	(81%	white)	median	age	66	(range	50-85)years	doses	received	6	1-21)	psa	responsewas	observed	12	40	(30%	95%	ci	18%-45%)	measurable	diseaseresponse	19	(32%	[95%	15%-54%])	conversions	13	26(50%	32%-68%)	radiographic	progression-free	9	9(95%	1-12	6)	months	use	epic	sciences	non-epcam-based	ctcdetection	platform	detected	16	18	(89%)	11	(61%)had	above	analytical	threshold	level	(psmapositive)	baseline	0	4-72	4	ctcs/ml)	psma-positivectcs	preferentially	reduced	treatment-related	adverse	events	grade1	fatigue	(29	[69%])	nausea	(23	[55%])	neuropathy	(14[33%])	neutropenic	fever	(1	[2%])	conclusions	relevance	these	findings	suggest	that	isactive	well	tolerated	antitumoractivity	may	be	related	levels	which	suggests	thatpatients	who	are	likely	benefit	this	can	identified	beforetreatment	initiated	trial	registration	clinicaltrials	gov	identifier	nct01812746
